Immunic Highlights Multiple Sclerosis Research Advancements at Key Conferences in September 2025

Immunic Showcases Advancements in Multiple Sclerosis Research at Key Conferences

Immunic, Inc., a biotechnology firm specializing in orally administered small molecule therapies for chronic inflammatory and autoimmune diseases, steps into the spotlight as it prepares for a series of significant investor and scientific conferences in September 2025. With a strategic focus on advancing its lead asset, vidofludimus calcium (IMU-838), the company aims to enhance its visibility and foster relationships within the scientific community. President and COO Jason Tardio is set to provide a comprehensive company overview at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, highlighting the company’s innovative pipeline and commitment to addressing unmet medical needs in the realm of chronic inflammatory conditions.

Following the H.C. Wainwright conference, Immunic will participate in the 2025 Leerink Partners Biopharma Summit, where CEO Daniel Vitt, Ph.D., will further discuss the company’s strategic direction. However, the highlight of Immunic's September agenda is the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), taking place from September 24-26 in Barcelona, Spain. During this pivotal event, Immunic will present critical findings on vidofludimus calcium, emphasizing its role as a novel Nurr1 activator and selective DHODH inhibitor. An oral presentation scheduled for September 24 at 2:35 PM CEST will detail the efficacy and safety of this promising therapy in treating progressive multiple sclerosis, thereby contributing to the scientific discourse surrounding innovative treatment options for this challenging condition.

Moreover, Immunic plans to unveil additional data through a late-breaking poster presentation that explores the efficacy and safety of vidofludimus calcium in Primary Progressive Multiple Sclerosis. This presentation will draw on subpopulation data from the Phase 2 CALLIPER Trial, underscoring the company's dedication to rigorous clinical research and its implications for patient care. Immunic's presence at booth #B37 during ECTRIMS will provide attendees with an opportunity to engage with the team and access comprehensive conference materials available on the company’s website. Through these strategic presentations and interactions, Immunic seeks to solidify its position as a leader in the field of multiple sclerosis treatment and research.

In addition to these conferences, Immunic's participation highlights its ongoing commitment to transparency and investor engagement. The company recognizes the importance of sharing its scientific advancements and fostering dialogue with stakeholders, which is essential for driving innovation in the biopharmaceutical industry. As Immunic navigates these key events, its focus remains on delivering impactful therapies that address the complexities of inflammatory and autoimmune diseases.